Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Fonds National de la Recherche Scientifique | OTHER |
Not provided
Not provided
Not provided
Not provided
Background & Rationale:
Treatment options for Parkinson's Disease (PD) often face challenges due to the variety of clinical subtypes, differing individual responses, and disease progression. Given its portability, affordability, safety, and ease of use, cerebellar transcranial direct current stimulation (ctDCS) presents as a promising option for home-based treatment with medical telemonitoring in the near future.
Study Procedures:
Participants are invited to complete questionnaires regarding quality of life, anxiety and depression, and symptoms related to their PD.
On the first day, they will be assessed using the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III for motor impairment and the Cerebellar Cognitive Affective Syndrome scale (CCAS) for cognitive impairment. Participants will then undergo an additional 8 days of at-home cTDCS stimulation. On the 10th day, they will be reassessed using the MDS-UPDRS III and CCAS. One month later, they will complete again the questionnaires regarding quality of life, anxiety, depression, and symptoms related to their PD.
Objective:
Consequently, the primary goal is to investigate the effectiveness of ctDCS in addressing both motor and non-motor symptoms of PD
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| anodal cTDCS group | Experimental |
| |
| cathodal cTDCS group | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| cTDCS | Device | anodal cTDCS |
| |
| cTDCS |
| Measure | Description | Time Frame |
|---|---|---|
| MDS-UPDRS (Unit on a scale) | MDS-UPDRS Part III MDS-UPDRS Part I, II and IV | day 1 to day 10 (MDS-UPDRS III) day 1 to day 40 (MDS-UPDRS Part I, II and IV) |
| CCAS (Unit on a scale) | CCAS scale | day 1 and day 10 |
| Measure | Description | Time Frame |
|---|---|---|
| Feasibility and tolerability of ctDCS (Unit on a scale) | participant-reported outcomes regarding the ease of self-administration and the presence of side effects are collected through a dedicated questionnaire. | from day 1 to day 10 |
| Scale evaluation anxiety (Unit on a scale) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hopital Erasme | Brussels | 1070 | Belgium |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 34813040 | Background | Manto M, Argyropoulos GPD, Bocci T, Celnik PA, Corben LA, Guidetti M, Koch G, Priori A, Rothwell JC, Sadnicka A, Spampinato D, Ugawa Y, Wessel MJ, Ferrucci R. Consensus Paper: Novel Directions and Next Steps of Non-invasive Brain Stimulation of the Cerebellum in Health and Disease. Cerebellum. 2022 Dec;21(6):1092-1122. doi: 10.1007/s12311-021-01344-6. Epub 2021 Nov 23. | |
| 41616661 |
Not provided
Not provided
anonymous.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010300 | Parkinson Disease |
| ID | Term |
|---|---|
| D020734 | Parkinsonian Disorders |
| D001480 | Basal Ganglia Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
Three months post-stimulation, patients will cross over to the other study group
Not provided
Not provided
MDS-UPDRS III is recorded by a blinded neurologist CCAS is recorded by a blinded neuropsychologist
| Device |
cathodal cTDCS |
|
anxiety as evaluated by Generalized Anxiety Disorder-7 (GAD-7) |
| day 1 and day 40 |
| Scale evaluating depression (Unit on a scale) | depression as evaluated by Patient Health Questionnaire-9 (PHQ-9 ) | day 1 and day 40 |
| Quality of life (Unit on a scale) | quality of life as evaluated by Parkinson's Disease Questionnaire-39 (PDQ-39) | day 1 and day 40 |
| Scale evaluation anxiety (Unit on a scale) | anxiety as evaluated by Beck Anxiety Inventory (BAI) | day 1 and day 40 |
| Scale evaluating depression (Unit on a scale) | depression as evaluated by Beck Depression Inventory (BDI) | day 1 and day 40 |
| Quality of life (Unit on a scale) | quality of life as evaluated by European Quality of Life 5 Dimensions (EQ-5D) | day 1 and day 40 |
| Background |
| Cabaraux P, Georgiev C, Destrebecq V, Supiot F, Munoz NY, Hakkak Moghadam Torbati A, Digileva D, Iannotta A, Yildiran Carlak E, Mongold S, Bourguignon M, Naeije G. Effects of anodal cerebellar transcranial direct current stimulation on motor symptoms and cerebellar inhibition in Parkinson's disease: A sham-controlled cross-over study. Parkinsonism Relat Disord. 2026 Mar;144:108202. doi: 10.1016/j.parkreldis.2026.108202. Epub 2026 Jan 28. |
| D009422 | Nervous System Diseases |
| D009069 | Movement Disorders |
| D000080874 | Synucleinopathies |
| D019636 | Neurodegenerative Diseases |